Skip to main
RNXT

RenovoRx (RNXT) Stock Forecast & Price Target

RenovoRx (RNXT) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

RenovoRx Inc. demonstrated notable revenue growth in Q2, achieving $422K, a substantial increase from $197K in Q1. The company is forecasted to experience significant revenue expansion, with projections of $1.3 million in 2025 and $4.5 million in 2026. This anticipated growth is underpinned by RenovoRx's innovative proprietary therapies designed to address high unmet medical needs in cancer treatment, offering a promising outlook for the company's financial performance moving forward.

Bears say

RenovoRx reported revenue of $0.3 million to $0.4 million alongside a net loss of $2.9 million, which resulted in an earnings per share (EPS) of $(0.08) and did not deviate from consensus estimates. The company operates in the challenging field of pancreatic cancer treatment, which has the most dismal 5-year survival rate of just 12%, underscoring the high unmet medical need and potential market difficulties. While there are considerations for growth prospects and valuation, the persistent net losses and tepid revenue performance highlight fundamental concerns that may warrant a negative outlook on the company’s financial viability.

RenovoRx (RNXT) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of RenovoRx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About RenovoRx (RNXT) Forecast

Analysts have given RenovoRx (RNXT) a Strong Buy based on their latest research and market trends.

According to 2 analysts, RenovoRx (RNXT) has a Strong Buy consensus rating as of Feb 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

RenovoRx (RNXT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.